Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies)

Current Opinion in Oncology

Volumn 18, Issue 4, 2006, Pages 307-315

  De Castro Jr , Gilberto ^a   Awada, Ahmad ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Anti angiogenic agents; Bortezomib; Farnesyltransferase inhibitors; Lenalidomide; Molecular targeted therapies; Tyrosine kinase inhibitors

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CEPHALOSPORIN DERIVATIVE; CISPLATIN; DASATINIB; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; LAPATINIB; LENALIDOMIDE; LONAFARNIB; NILOTINIB; PACLITAXEL; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VATALANIB;

ABDOMINAL BLEEDING; ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALOPECIA; ANEMIA; ANOREXIA; ARTERY EMBOLISM; ASTHENIA; BIPOLAR DISORDER; BLEEDING; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONSTIPATION; CORRELATION ANALYSIS; DEEP VEIN THROMBOSIS; DEPIGMENTATION; DEPRESSION; DERMATITIS; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRY SKIN; DUODENUM ULCER; DYSPNEA; EDEMA; FATIGUE; FLUID RETENTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEART DISEASE; HERPES ZOSTER; HUMAN; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY CARCINOMA; LETHALITY; LUNG EMBOLISM; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MACULOPAPULAR RASH; MOUTH PAIN; MUCOSA INFLAMMATION; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; PAIN; PANCREATITIS; PATHOPHYSIOLOGY; PENIS DISEASE; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; SKIN TOXICITY; SOMNOLENCE; SPINAL CORD COMPRESSION; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VOMITING; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; BORONIC ACIDS; DRUG DESIGN; FARNESYLTRANSTRANSFERASE; HUMANS; IMMUNOLOGIC FACTORS; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-TYROSINE KINASES; PYRAZINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THALIDOMIDE;

EID: 33748079780     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000228733.55132.ea     Document Type: Review

References (74)

1. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005; 352:895-904.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
3. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
4. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101:13306-13311.
5. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-1537. This phase III study investigated the effect on survival of gefitinib as second-line or third-line treatment for patients with locally advanced or metastatic NSCLC. The median survival did not differ significantly between the groups in the overall population or among patients with adenocarcinoma, but subgroup analyses showed significantly longer survival in the gefitinib group for never-smokers and patients of Asian origin.
6. Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 2006; 24:64-69. The authors observed a response rate of 30% in this phase II trial of gefitinib as a first-line treatment in patients with NSCLC, but the incidence of ILD was very high.
7. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22:777-784.
8. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22:785-794.
9. Seto T, Yamamoto N. Interstitial lung disease induced by gefitinib in patients with advanced non-small cell lung cancer: results of a West Japan Thoracic Oncology Group (WJTOG) epidemiological survey. J Clin Oncol 2004; 22 (14S):632.
10. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132. This phase III trial demonstrated that erlotinib is superior to placebo in terms of response rate, median duration of the response, progression-free survival and overall survival, with good tolerability, after first-line or second-line chemotherapy.
11. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
12. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20:2240-2250.
13. Van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147:598-601.
14. Herbst RS, LoRusso PM, Purdom M, et al. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003; 4:366-369.
15. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-5899.
16. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 2004; 22 (14S):617.
17. Clark G, Perez-Soler R, Siu L, et al. Rash severity is predictive of increased survival with erlotinib HCI. Proc Am Soc Clin Oncol 2003; 22:196.
18. Miller VA, Johnson D, Heelan RT, et al. A pilot trial demonstrates the safety of ZD1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor, in combination with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2001; 20:326a.
19. West H, Franklin WA, Gumerlock PH, et al. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer: Southwest Oncology Group study S0126. J Clin Oncol 2004; 22 (14S):618.
20. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21:1980-1987.
21. Cho C, Fisher D, Halsey J, et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with unresectable or metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003; 22:265.
22. Perea S, Oppenheimer D, Amador M, et al. Genotypic bases of EGFR inhibitors pharmacological actions. J Clin Oncol 2004; 22 (14S):196.
23. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23:5235-5246.
24. Baselga J. Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough? Clin Cancer Res 2003; 9:2389-2390.
25. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267-3279.
26. Burris HA III, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23:5305-5313. Lapatinib was well tolerated and clinical activity was observed in heavily pretreated patients with Her-1-expressing and/or Her-2-overexpressing metastatic cancers.
27. Blackwell KL, Kaplan EH, Franco SX, et al. A phase II, open-label, multicenter study of lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on trastuzumab-containig regimens. Ann Oncol 2004; 15 (Suppl 3):27.
28. Smith DA, Bowen C, Herendeen JM, et al. An open-label, randomized, twoway crossover study to evaluate the potential inhibition of GW570216 metabolism by ketoconazol. J Clin Oncol 2004; 22 (14S):212.
29. Krause DS, Van Etten R. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353:172-187.
30. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
31. Zipfel PA, Zhang W, Quiroz M, et al. Requirement for Abl kinases in T cell receptor signaling. Curr Biol 2004; 14:1222-1231.
32. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-480.
33. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305:399-401.
34. Sawyers CL, Shah NP, Kantarjian HM, et al. A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant accelerated and blast phase chronic myeloid leukemia: results from CA180002. J Clin Oncol 2005; 23 (16S):565.
35. Talpaz M, Kantarjian HM, Paquette R, et al. A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia: results from CA180002. J Clin Oncol 2005; 23 (16S):564.
36. Kantarjian H, Ottmann O, Cortes J, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant bcr-abl positive chronic myeloid leukemia. J Clin Oncol 2005; 23 (16S):195.
37. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Cin Oncol 2006; 24:25-35.
38. Demetri GD, van Oosterom AT, Garret C, et al. Sunitinib maleate (SU11248) prolongs progression-free and overall survial for GIST patients after failure of imatinib mesylate therapy: update of a phase III trial. Eur J Cancer Suppl 2005; 3:203.
39. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24. This phase II study revealed that sunitinib has antitumor activity in metastatic renal cell carcinoma as second-line therapy, after first-line cytokine therapy, with an overall response rate of 40% and a median overall survival of 8.7 months.
40. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965-972.
41. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92:1855-1861.
42. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16:1688-1694.
43. Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11:5472-5480.
44. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma. J Clin Oncol 2005; 23 (16S):380.
45. Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 2006; 42:548-556. In patients treated with sorafenib at or close to the recommended dose of 400 mg twice daily in phase II/III trials, 15% presented grade 2 or 3 hand/foot syndrome, and 24% presented grade 2/3 diarrhea. This pooled analysis suggests that those who experienced skin toxicity/diarrhea had a significantly increased time to tumor progression compared with patients without such toxicity.
46. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; Jan 30 [Epub ahead of print].
47. Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK222584 or placebo (CONFIRM-1). J Clin Oncol 2005; 23 (16S):3.
48. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62:4645-4655.
49. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005; 16:1391-1397.
50. Miller KD, Trigo JM, Wheeler C, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005; 11:3369-3376.
51. Johnson BE, Ma P, West H, et al. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC. J Clin Oncol 2005; 23 (16S):645.
52. Heymach JV, Johnson BE, Rowbottom JA, et al. A randomized, placebo-controlled Phase II trial of ZD6474 plus docetaxel, in patients with NSCLC. J Clin Oncol 2005; 23 (16S):197.
53. Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001; 7:1758-1764.
54. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22:2336-2347.
55. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23:5294-5304.
56. Chan S, Scheulen ME, Jonhston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23:5314-5322.
57. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22:909-918.
58. O'Donnell A, Faivre S, Judson I, et al. A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic and pharmacodynamic endpoints in patients with solid tumours. Proc Am Soc Clin Oncol 2003; 22:200.
59. Tabernero J, Rojo F, Burris H, et al. A phase I study with tumor molecular pharmacodynamic evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients with advanced solid tumors. J Clin Oncol 2005; 23 (16S):193.
60. Cohen SJ, Ho L, Ranganathan S, et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2003; 21:1301-1306.
61. Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:1760-1766.
62. Siegel-Lakhai WS, Crul M, Zhang S, et al. Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. Br J Cancer 2005; 93:1222-1229.
63. Sharma S, Kemeny N, Kelsen DP, et al. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol 2002; 13:1067-1071.
64. Awada A, Eskens FA, Piccart M, et al. Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur J Cancer 2002; 38:2272-2278.
65. Kim ES, Kies MS, Fossella FV, et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 2005; 104:561-569.
66. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-3076.
67. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101:1530-1534.
68. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99:14374-14379.
69. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62:4996-5000.
70. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-2498. This phase III study demonstrated that bortezomib is superior to high-dose dexamethasone in patients with relapsed multiple myeloma after one to three previous therapies, in terms of response rate, time to progression and overall survival.
71. Berenson JR, Jagannath S, Barlogie B, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005; 104:2141-2148.
72. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100:3063-3067.
73. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352:549-557. In this phase II study, lenalidomide presented some hematologic activity in patients with low-risk myelodysplastic syndromes, especially in those presenting clonal interstitial deletion involving chromosome 5q31.1, who have no response to erythropoietin or who are unlikely to benefit from conventional therapy.
74. Bartlett JB, Michael A, Clarke IA, et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004; 90:955-961.